NCT07496918

Brief Summary

Despite the huge healthcare and economic impact of AD, there is still no disease modifying therapeutics available. In fact, the available therapeutics show low efficacy at best in the treatment of cognitive impairment in dementia. Development of a non-invasive medical device that is effective in slowing cognitive impairment is not only revolutionary but also possibly cost- effective. In this study, participants will come to MIT for a 1-day visit and the investigators will evaluate the effects of GENUS in cognitively normal, healthy adults. Investigators will use Electroencephalogram (EEG), Magnetoencephalography (MEG), magnetic resonance imaging (MRI), neuropsychological testing, and blood sampling in subsets of participants to evaluate for biological effects and safety of GENUS stimulation.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for phase_2

Timeline
6mo left

Started Feb 2018

Longer than P75 for phase_2

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress94%
Feb 2018Jan 2027

Study Start

First participant enrolled

February 20, 2018

Completed
6.9 years until next milestone

First Submitted

Initial submission to the registry

January 9, 2025

Completed
1.2 years until next milestone

First Posted

Study publicly available on registry

March 27, 2026

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 30, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 30, 2027

Last Updated

March 27, 2026

Status Verified

March 1, 2026

Enrollment Period

8.9 years

First QC Date

January 9, 2025

Last Update Submit

March 24, 2026

Conditions

Outcome Measures

Primary Outcomes (3)

  • Effects of GENUS on brain oscillations

    Using Electroencephalogram (EEG), investigators will determine whether GENUS will affect brain oscillations, including those in the gamma band.

    1 year

  • Effects of GENUS on brain oscillations

    Using Magnetoencephalography (MEG), investigators will determine whether GENUS will affect brain oscillations.

    1 year

  • Effects of GENUS on brain oscillations

    Using magnetic resonance imaging (MRI), investigators will determine whether GENUS will affect brain oscillations.

    1 year

Other Outcomes (7)

  • Effects of GENUS on the microbiome

    1 year

  • Effect of GENUS on blood biomarkers

    1 year

  • Effect of GENUS on brain connectivity

    1 year

  • +4 more other outcomes

Study Arms (1)

Cognitively normal adults

EXPERIMENTAL

Cognitively normal, healthy adults aged 18 - 100

Device: GENUSDevice: Tactile GENUS

Interventions

GENUSDEVICE

The device is a light and sound device that delivers light stimulation using light-emitting diodes (LED) and sound stimulation through a speaker, with a centrally-mounted tablet or phone that plays videos for entertainment. The device will be positioned on an easel such that the tablet is eye level with the participant while they are sitting 5 feet away or held in their hands. The active device delivers light and sound at 40Hz rate.

Cognitively normal adults

The device is a wrist worn or hand held device that vibrates or otherwise generates tactile stimulation at specific frequencies.

Cognitively normal adults

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Have adequate visual and auditory acuity for visual and auditory stimulation to allow for neuropsychological testing.
  • Be able to comply with neuropsychological testing and other study procedures in opinion of site PI.

You may not qualify if:

  • History of seizure or medical diagnosis of epilepsy.
  • Have MRI contraindications, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body.
  • Under the discretion of the site investigator, the site investigator feels the subject cannot complete sufficient key study procedures. Exceptions to these guidelines may be considered on a case-by-case basis at the discretion of the Project Director.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

MIT

Cambridge, Massachusetts, 02139, United States

RECRUITING

Related Publications (1)

  • Chan D, Suk HJ, Jackson BL, Milman NP, Stark D, Klerman EB, Kitchener E, Fernandez Avalos VS, de Weck G, Banerjee A, Beach SD, Blanchard J, Stearns C, Boes AD, Uitermarkt B, Gander P, Howard M 3rd, Sternberg EJ, Nieto-Castanon A, Anteraper S, Whitfield-Gabrieli S, Brown EN, Boyden ES, Dickerson BC, Tsai LH. Gamma frequency sensory stimulation in mild probable Alzheimer's dementia patients: Results of feasibility and pilot studies. PLoS One. 2022 Dec 1;17(12):e0278412. doi: 10.1371/journal.pone.0278412. eCollection 2022.

MeSH Terms

Conditions

Alzheimer Disease

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental Disorders

Study Officials

  • Ana Trisini Lipsanopoulos, BS

    Massachusetts Institute of Technology

    STUDY DIRECTOR

Central Study Contacts

Ana Trisini Lipsanopoulos, BS

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SEQUENTIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 9, 2025

First Posted

March 27, 2026

Study Start

February 20, 2018

Primary Completion (Estimated)

January 30, 2027

Study Completion (Estimated)

January 30, 2027

Last Updated

March 27, 2026

Record last verified: 2026-03

Locations